MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
Grade
Moligand™
Product Description
Information
MCC950 MCC950 is a potent and selective inhibitor of NLRP3 with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
MCC950 is a potent, selective, small molecule inhibitor of NLRP3. MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. MCC950 is active in ex vivo samples from individuals with Muckle-Wells syndrome.
In vivo
MCC950 reduces Interleukin-1p (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS.
Cell Research(from reference)
Cell lines：BMDM, HMDM, PBMC, HEK293T cells
Concentrations：0.001 μM–10 μM, 5 nM–1000 nM
Incubation Time：30 min, 45 min
Associated Targets(Human)
NLRP3TchemNACHT, LRR and PYD domains-containing protein 3 (8 Activities)
